NDV-3A: Phase Ib/IIa started

NovaDigm began a double-blind, placebo-controlled, U.S. Phase Ib/IIa trial to evaluate single intramuscular vaccinations of NDV-3A in about 189 patients with recurrent vulvovaginal candidiasis. The Ph...